Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,138 public posts
Filter results
Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
INTERPRETATION Olaparib has antitumour activity against metastatic
castration
-resistant prostate cancer with DDR gene aberrations, supporting the implementation of genomic stratification of metastatic
castration
-resistant prostate cancer in clinical practice.
INTERPRETATION Olaparib has antitumour activity against metastatic
castration
-resistant prostate cancer with DDR gene aberrations, supporting the implementation of genomic stratification of metastatic
castration
-resistant prostate cancer in clinical practice.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Statin use in advanced PCA with ADT or abiraterone/enzalutamide
However, it could not generate reliable evidence in patients with metastatic
castration
-resistant prostate cancer (mCRPC) treated with abiraterone/enzalutamide, as relevant studies were limited and had inconsistent results."
However, it could not generate reliable evidence in patients with metastatic
castration
-resistant prostate cancer (mCRPC) treated with abiraterone/enzalutamide, as relevant studies were limited and had inconsistent results."
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Testosterone & Docetaxel in CRPC.
Abstract BACKGROUND: The role of testosterone as a prognostic factor for
castration
-resistant prostate cancer treated with docetaxel in Japan was investigated.
Abstract BACKGROUND: The role of testosterone as a prognostic factor for
castration
-resistant prostate cancer treated with docetaxel in Japan was investigated.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Criteria for Commencement of Next Line Therapy
Most of the oncologists that I have talked to date consider a PSA of 2 ng/ml as the threshold for classifying a patient as
castration
resistant and before commencing the next line of therapy.
Most of the oncologists that I have talked to date consider a PSA of 2 ng/ml as the threshold for classifying a patient as
castration
resistant and before commencing the next line of therapy.
PhilipSZacarias
in
Advanced Prostate Cancer
5 years ago
Definition of Castration Resistant PCA
Can someone tell me what defines mcrPC?
Can someone tell me what defines mcrPC?
roke
in
Advanced Prostate Cancer
5 years ago
Optimal chemohormonal sequencing for metastatic castration-resistant prostate cancer MAY be Taxotere->Zytiga->Jevtana->Xtandi
Alternating chemos and hormonals like this seems to be optimal for metastatic
castration
-resistant prostate cancer (mCRPC). Other therapies may be able to be piggybacked so they can be tried sooner. https://pcnrv.blogspot.com/2019/12/optimal-chemohormonal-sequencing-for.html
Alternating chemos and hormonals like this seems to be optimal for metastatic
castration
-resistant prostate cancer (mCRPC). Other therapies may be able to be piggybacked so they can be tried sooner. https://pcnrv.blogspot.com/2019/12/optimal-chemohormonal-sequencing-for.html
Tall_Allen
in
Advanced Prostate Cancer
5 years ago
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer
TAKE-HOME MESSAGE •The authors report on 3 cohorts of patients with metastatic
castration
-resistant prostate cancer treated with pembrolizumab in the phase II KEYNOTE-199 trial.
TAKE-HOME MESSAGE •The authors report on 3 cohorts of patients with metastatic
castration
-resistant prostate cancer treated with pembrolizumab in the phase II KEYNOTE-199 trial.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Survival With Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer in Clinical Practice
•Overall survival with cabazitaxel in a real-world cohort of patients with metastatic
castration
-resistant prostate cancer was shorter than previously reported in clinical trials.
•Overall survival with cabazitaxel in a real-world cohort of patients with metastatic
castration
-resistant prostate cancer was shorter than previously reported in clinical trials.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Significance of BRCA2 and RB1 Co-Loss in Aggressive Prostate Cancer Progression
RESULTS In human prostate cancer cell lines (LNCaP and LAPC4), loss of BRCA2 leads to the
castration
-resistant phenotype.
RESULTS In human prostate cancer cell lines (LNCaP and LAPC4), loss of BRCA2 leads to the
castration
-resistant phenotype.
Balsam01
in
Advanced Prostate Cancer
5 years ago
Circulating oestrogen receptor mutations and splice variants in advanced prostate cancer.
The presence of ER mutations was associated with bone metastases and
castration
resistance. ERβ splice variant concentrations decreased after successive lines of treatment. Conclusions The ER mutations were detectable in plasma from patients with advanced prostate cancer.
The presence of ER mutations was associated with bone metastases and
castration
resistance. ERβ splice variant concentrations decreased after successive lines of treatment. Conclusions The ER mutations were detectable in plasma from patients with advanced prostate cancer.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
query=TOC BACKGROUND The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic
castration
-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while
query=TOC BACKGROUND The efficacy and safety of cabazitaxel, as compared with an androgen-signaling–targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic
castration
-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months while
MateoBeach
in
Advanced Prostate Cancer
5 years ago
enzalutamide (XTANDI®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC).
On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI®, Astellas Pharma Inc.) for patients with metastatic
castration
-sensitive prostate cancer (mCSPC). FDA previously approved enzalutamide for patients with
castration
-resistant prostate cancer.
On December 16, 2019, the Food and Drug Administration approved enzalutamide (XTANDI®, Astellas Pharma Inc.) for patients with metastatic
castration
-sensitive prostate cancer (mCSPC). FDA previously approved enzalutamide for patients with
castration
-resistant prostate cancer.
Darryl
Partner
in
Advanced Prostate Cancer
5 years ago
Saw MO yesterday
He gave me an infusion (cannot remember the name) to strengthen my bones and prescribed Casodex, he also discussed surgery, not full
castration
but just to snip the lines so to speak, which I agreed to.
He gave me an infusion (cannot remember the name) to strengthen my bones and prescribed Casodex, he also discussed surgery, not full
castration
but just to snip the lines so to speak, which I agreed to.
Zetabow
in
Advanced Prostate Cancer
5 years ago
Enzalutamide and PSMA
In an attempt to find the best condition for PSMA radioligand therapy in metastatic
castration
-resistant prostate cancer (mCRPC) patients, we evaluated the effect of oral enzalutamide in patients, predominantly having previously progressed on enzalutamide treatment.
In an attempt to find the best condition for PSMA radioligand therapy in metastatic
castration
-resistant prostate cancer (mCRPC) patients, we evaluated the effect of oral enzalutamide in patients, predominantly having previously progressed on enzalutamide treatment.
Blair77
in
Advanced Prostate Cancer
5 years ago
Weakness and fatigue on abiraterone plus Prednisone
My father diagnosed Gleason 4+4= 8 Gleason 3 Mets PCA it's yet
castration
sensitive...not turned into resistant since 2 years he's been on 12 week palmorelin hormone treatment injection and abiraterone 1000 mg plus Prednisone 5 mg nowadays he's feeling weak and fatigued and it's kind of fluctuating energy
My father diagnosed Gleason 4+4= 8 Gleason 3 Mets PCA it's yet
castration
sensitive...not turned into resistant since 2 years he's been on 12 week palmorelin hormone treatment injection and abiraterone 1000 mg plus Prednisone 5 mg nowadays he's feeling weak and fatigued and it's kind of fluctuating energy
Nirman
in
Advanced Prostate Cancer
5 years ago
Docetaxel & PSA time to nadir.
Prostate Cancer Consortium Abstract Objective Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic
castration
-resistant prostate cancer (mCRPC) in China.
Prostate Cancer Consortium Abstract Objective Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic
castration
-resistant prostate cancer (mCRPC) in China.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
More data from the LATITUDE study.
KEYWORDS: Abiraterone; Metastatic
castration
-sensitive prostate cancer; Overall survival; Prostate-specific antigen kinetics; Radiological progression-free survival PMID: 31843335 DOI: 10.1016/j.eururo.2019.11.021
KEYWORDS: Abiraterone; Metastatic
castration
-sensitive prostate cancer; Overall survival; Prostate-specific antigen kinetics; Radiological progression-free survival PMID: 31843335 DOI: 10.1016/j.eururo.2019.11.021
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Flutamide"
Abstract Currently, the early introduction of new antiandrogens is popular for
castration
-resistant prostate cancer (CRPC). However, adverse events can be severe and their costs are high. Here, we present a patient with CRPC in whom flutamide controlled disease progression for 10 years.
Abstract Currently, the early introduction of new antiandrogens is popular for
castration
-resistant prostate cancer (CRPC). However, adverse events can be severe and their costs are high. Here, we present a patient with CRPC in whom flutamide controlled disease progression for 10 years.
pjoshea13
in
Advanced Prostate Cancer
5 years ago
LiverTox docs
Therapy with apalutamide lowers residual testosterone levels after surgical
castration
in men with prostate cancer and has been shown to prolong metastatic free survival in men with
castration
-resistant prostate cancer with rising levels of prostate-associated antigen (PSA) without measurable metastatic
Therapy with apalutamide lowers residual testosterone levels after surgical
castration
in men with prostate cancer and has been shown to prolong metastatic free survival in men with
castration
-resistant prostate cancer with rising levels of prostate-associated antigen (PSA) without measurable metastatic
pjoshea13
in
Advanced Prostate Cancer
5 years ago
Orchiectomy rather than chemical castration?
If they were not, he recommends an orchiectomy rather than chemical
castration
due to concern about allergic reaction to a different medicine. Do you fellows think this is a good approach or would a different path be better? Thanks
If they were not, he recommends an orchiectomy rather than chemical
castration
due to concern about allergic reaction to a different medicine. Do you fellows think this is a good approach or would a different path be better? Thanks
Muchacho
in
Advanced Prostate Cancer
5 years ago
1
...
34
35
36
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1015 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest